{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:58:20Z","timestamp":1791845900602,"version":"4.3.4"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100015311","name":"Novartis Institutes for BioMedical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015311","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Respiratory Biomedical Research Unit"},{"name":"Royal Brompton and Harefield National Health Service Foundation Trust and Imperial College"},{"name":"National Health Service"},{"DOI":"10.13039\/501100000272","name":"The National Institute for Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Rationale<\/jats:title>\n                    <jats:p>Bimagrumab is a fully human monoclonal antibody that blocks the activin type II receptors, preventing the activity of myostatin and other negative skeletal muscle regulators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the effects of bimagrumab on skeletal muscle mass and function in patients with chronic obstructive pulmonary disease (COPD) and reduced skeletal muscle mass.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Sixty-seven patients with COPD (mean FEV1, 1.05 L [41.6% predicted]; aged 40\u201380 yr; body mass index\u2009&amp;lt;\u200920 kg\/m2 or appendicular skeletal muscle mass index\u2009\u2264\u20097.25 [men] and \u2264\u20095.67 [women] kg\/m2), received two doses of either bimagrumab 30 mg\/kg intravenously (n\u2009=\u200933) or placebo (n\u2009=\u200934) (Weeks 0 and 8) over 24 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements and Main Results<\/jats:title>\n                    <jats:p>We assessed changes in thigh muscle volume (cubic centimeters) as the primary endpoint along with 6-minute-walk distance (meters), safety, and tolerability. Fifty-five (82.1%) patients completed the study. Thigh muscle volume increased by Week 4 and remained increased at Week 24 in bimagrumab-treated patients, whereas no changes were observed with placebo (Week 4: +5.9% [SD, 3.4%] vs. 0.0% [3.3%], P\u2009&amp;lt;\u20090.001; Week 8: +7.0% [3.7%] vs. \u22120.7% [2.8%], P\u2009&amp;lt;\u20090.001; Week 16: +7.8% [5.1%] vs. \u22120.9% [4.5%], P\u2009&amp;lt;\u20090.001; Week 24: +5.0% [4.9%] vs. \u22121.3% [4.3%], P\u2009&amp;lt;\u20090.001). Over 24 weeks, 6-minute-walk distance did not increase significantly in either group. Adverse events in the bimagrumab group included muscle-related symptoms, diarrhea, and acne, most of which were mild in severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Blocking the action of negative muscle regulators through the activin type II receptors with bimagrumab treatment safely increased skeletal muscle mass but did not improve functional capacity in patients with COPD and low muscle mass.<\/jats:p>\n                    <jats:p>Clinical trial registered with www.clinicaltrials.gov (NCT01669174).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201802-0286oc","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T13:20:41Z","timestamp":1533907241000},"page":"313-320","source":"Crossref","is-referenced-by-count":105,"title":["Activin Type II Receptor Blockade for Treatment of Muscle Depletion in Chronic Obstructive Pulmonary Disease. A Randomized Trial"],"prefix":"10.1093","volume":"199","author":[{"given":"Michael I.","family":"Polkey","sequence":"first","affiliation":[{"name":"National Institute for Health Research Respiratory Biomedical Research Unit, Royal Brompton and Harefield National Health Service Foundation Trust and Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Praestgaard","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Berwick","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits M. E.","family":"Franssen","sequence":"additional","affiliation":[{"name":"Department of Research and Education, CIRO, Center of Expertise for Chronic Organ Failure, Horn, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[{"name":"Centre for Respiratory Medicine and Allergy, University of Manchester and the Medicines Evaluation Unit, University Hospital of South Manchester National Health Service Foundation Trust, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Steiner","sequence":"additional","affiliation":[{"name":"Centre for Exercise and Rehabilitation Science, National Institute for Health Research Leicester Biomedical Research Centre, Respiratory, Glenfield Hospital, Leicester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Casaburi","sequence":"additional","affiliation":[{"name":"Rehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute, Harbor-University of California Los Angeles Medical Center, Torrance, California; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanns-Christian","family":"Tillmann","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"Lach-Trifilieff","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronenn","family":"Roubenoff","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Rooks","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"key":"2026030321242901700_bib1","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1183\/09031936.00170111","article-title":"Quadriceps wasting and physical inactivity in patients with COPD","volume":"40","author":"Shrikrishna","year":"2012","journal-title":"Eur Respir J"},{"key":"2026030321242901700_bib2","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/thx.2006.062026","article-title":"Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease","volume":"62","author":"Swallow","year":"2007","journal-title":"Thorax"},{"key":"2026030321242901700_bib3","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1164\/rccm.2107031","article-title":"Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease","volume":"166","author":"Marquis","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321242901700_bib4","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1164\/rccm.201503-0535OC","article-title":"Bedside assessment of quadriceps muscle by ultrasound after admission for acute exacerbations of chronic respiratory disease","volume":"192","author":"Greening","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321242901700_bib5","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa040933","article-title":"Myostatin mutation associated with gross muscle hypertrophy in a child","volume":"350","author":"Schuelke","year":"2004","journal-title":"N Engl J Med"},{"key":"2026030321242901700_bib6","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1101\/gr.7.9.910","article-title":"Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle","volume":"7","author":"Kambadur","year":"1997","journal-title":"Genome Res"},{"key":"2026030321242901700_bib7","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1183\/09031936.00032510","article-title":"Quadriceps myostatin expression in COPD","volume":"36","author":"Man","year":"2010","journal-title":"Eur Respir J"},{"key":"2026030321242901700_bib8","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/jcmm.12390","article-title":"Reduced myotube diameter, atrophic signalling and elevated oxidative stress in cultured satellite cells from COPD patients","volume":"19","author":"Pomi\u00e8s","year":"2015","journal-title":"J Cell Mol Med"},{"key":"2026030321242901700_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0002-9343(00)00472-1","article-title":"Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial","volume":"109","author":"Troosters","year":"2000","journal-title":"Am J Med"},{"key":"2026030321242901700_bib10","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1164\/rccm.200908-1203OC","article-title":"Resistance training prevents deterioration in quadriceps muscle function during acute exacerbations of chronic obstructive pulmonary disease","volume":"181","author":"Troosters","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321242901700_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1183\/09031936.00112909","article-title":"Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD","volume":"36","author":"Vogiatzis","year":"2010","journal-title":"Eur Respir J"},{"key":"2026030321242901700_bib12","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.chest.2016.05.038","article-title":"Pulmonary rehabilitation as a mechanism to reduce hospitalizations for acute exacerbations of COPD: a systematic review and meta-analysis","volume":"150","author":"Moore","year":"2016","journal-title":"Chest"},{"key":"2026030321242901700_bib13","first-page":"CD005305","article-title":"Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease","volume":"12","author":"Puhan","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026030321242901700_bib14","article-title":"Pulmonary rehabilitation: beyond breathing better","volume-title":"National Chronic Obstructive Pulmonary Disease (COPD) Audit Programme: outcomes from the clinical audit of pulmonary rehabilitation services in England 2015","author":"Steiner","year":"2017"},{"key":"2026030321242901700_bib15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","article-title":"Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial","volume":"3","author":"Becker","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026030321242901700_bib16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mus.23539","article-title":"A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers","volume":"47","author":"Attie","year":"2013","journal-title":"Muscle Nerve"},{"key":"2026030321242901700_bib17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1128\/MCB.01307-13","article-title":"An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy","volume":"34","author":"Lach-Trifilieff","year":"2014","journal-title":"Mol Cell Biol"},{"key":"2026030321242901700_bib18","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jgs.14927","article-title":"Treatment of sarcopenia with bimagrumab: results from a phase II, randomized, controlled, proof-of-concept study","volume":"65","author":"Rooks","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"2026030321242901700_bib19","author":"Global Initiative for Chronic Obstructive Lung Disease","year":"2018"},{"key":"2026030321242901700_bib20","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr"},{"key":"2026030321242901700_bib21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/nu8060359","article-title":"Protein consumption and the elderly: what is the optimal level of intake?","volume":"8","author":"Baum","year":"2016","journal-title":"Nutrients"},{"key":"2026030321242901700_bib22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/jmri.21699","article-title":"Accurate segmentation of subcutaneous and intermuscular adipose tissue from MR images of the thigh","volume":"29","author":"Positano","year":"2009","journal-title":"J Magn Reson Imaging"},{"key":"2026030321242901700_bib23","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1183\/09031936.02.00279602","article-title":"Bedside methods versus dual energy X-ray absorptiometry for body composition measurement in COPD","volume":"19","author":"Steiner","year":"2002","journal-title":"Eur Respir J"},{"key":"2026030321242901700_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321242901700_bib25","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/j.1532-5415.2008.01953.x","article-title":"Tests of muscle strength and physical function: reliability and discrimination of performance in younger and older men and older men with mobility limitations","volume":"56","author":"LeBrasseur","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"2026030321242901700_bib26","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.apmr.2007.02.004","article-title":"Is stair climb power a clinically relevant measure of leg power impairments in at-risk older adults?","volume":"88","author":"Bean","year":"2007","journal-title":"Arch Phys Med Rehabil"},{"key":"2026030321242901700_bib27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","article-title":"The timed \u201cUp & Go\u201d: a test of basic functional mobility for frail elderly persons","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J Am Geriatr Soc"},{"key":"2026030321242901700_bib28","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1164\/rccm.166.4.518","article-title":"ATS\/ERS statement on respiratory muscle testing","volume":"166","author":"American Thoracic Society\/European Respiratory Society","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321242901700_bib29","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure of health status for chronic airflow limitation: the St. George\u2019s Respiratory Questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"2026030321242901700_bib30","first-page":"13","article-title":"Safety, pharmacokinetics and pharmacodynamics of bimagrumab: a phase I, randomised, double-blind study in elderly and obese healthy human participants","volume":"6","author":"Rooks","year":"2017","journal-title":"J Frailty Aging"},{"key":"2026030321242901700_bib31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jamda.2011.06.009","article-title":"Predicting outcomes from 6-minute walk distance in chronic obstructive pulmonary disease","volume":"13","author":"Spruit","year":"2012","journal-title":"J Am Med Dir Assoc"},{"key":"2026030321242901700_bib32","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/thoraxjnl-2015-207046","article-title":"Gait speed and readmission following hospitalisation for acute exacerbations of COPD: a prospective study","volume":"70","author":"Kon","year":"2015","journal-title":"Thorax"},{"key":"2026030321242901700_bib33","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1164\/ajrccm.152.4.7551381","article-title":"Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease: a placebo-controlled randomized trial","volume":"152","author":"Schols","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321242901700_bib34","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1164\/rccm.200305-617OC","article-title":"Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease","volume":"170","author":"Casaburi","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321242901700_bib35","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1378\/chest.122.2.421","article-title":"Reversal of COPD-associated weight loss using the anabolic agent oxandrolone","volume":"122","author":"Yeh","year":"2002","journal-title":"Chest"},{"key":"2026030321242901700_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1378\/chest.114.1.19","article-title":"The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients","volume":"114","author":"Ferreira","year":"1998","journal-title":"Chest"},{"key":"2026030321242901700_bib37","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1164\/ajrccm.156.6.9704142","article-title":"Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease: a prospective, randomized, controlled study","volume":"156","author":"Burdet","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321242901700_bib38","doi-asserted-by":"crossref","first-page":"e35708","DOI":"10.1371\/journal.pone.0035708","article-title":"Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"7","author":"Miki","year":"2012","journal-title":"PLoS One"},{"key":"2026030321242901700_bib39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrd4467","article-title":"Muscle wasting in disease: molecular mechanisms and promising therapies","volume":"14","author":"Cohen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2026030321242901700_bib40","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/01.HCR.0000320074.73846.3b","article-title":"Locus of symptom limitation and exercise response to bronchodilation in chronic obstructive pulmonary disease","volume":"28","author":"Desch\u00eanes","year":"2008","journal-title":"J Cardiopulm Rehabil Prev"},{"key":"2026030321242901700_bib41","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1164\/rccm.200302-162OC","article-title":"Symptoms and quadriceps fatigability after walking and cycling in chronic obstructive pulmonary disease","volume":"168","author":"Man","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321242901700_bib42","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1164\/rccm.201508-1653OC","article-title":"The 6-minute-walk distance test as a chronic obstructive pulmonary disease stratification tool","volume":"194","author":"Celli","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321242901700_bib43","first-page":"410748","article-title":"Responsiveness of various exercise-testing protocols to therapeutic interventions in COPD","volume-title":"Pulm Med","author":"Borel","year":"2013"},{"key":"2026030321242901700_bib44","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1183\/09031936.00193411","article-title":"High-intensity knee extensor training restores skeletal muscle function in COPD patients","volume":"40","author":"Br\u00f8nstad","year":"2012","journal-title":"Eur Respir J"},{"key":"2026030321242901700_bib45","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1164\/ajrccm.154.5.8912741","article-title":"Diaphragm strength in chronic obstructive pulmonary disease","volume":"154","author":"Polkey","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321242901700_bib46","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1164\/ajrccm.160.2.9808067","article-title":"Functional magnetic stimulation of the abdominal muscles in humans","volume":"160","author":"Polkey","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321242901700_bib47","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1164\/ajrccm.158.3.9710072","article-title":"Expiratory muscle function in amyotrophic lateral sclerosis","volume":"158","author":"Polkey","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321242901700_bib48","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1164\/ajrccm.158.2.9711045","article-title":"Independent effects of etiology of failure and time to reintubation on outcome for patients failing extubation","volume":"158","author":"Epstein","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321242901700_bib49","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/mus.24289","article-title":"Bioenergetics and intermuscular fat in chronic obstructive pulmonary disease-associated quadriceps weakness","volume":"51","author":"Shields","year":"2015","journal-title":"Muscle Nerve"},{"key":"2026030321242901700_bib50","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/resp.12716","article-title":"Insulin resistance is associated with skeletal muscle weakness in COPD","volume":"21","author":"Wells","year":"2016","journal-title":"Respirology"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/199\/3\/313\/67119297\/ajrccm_199_3_313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/199\/3\/313\/67119297\/ajrccm_199_3_313.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:24:38Z","timestamp":1772591078000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/199\/3\/313\/8497752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,2,1]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201802-0286oc","relation":{},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,2]]},"published":{"date-parts":[[2019,2,1]]}}}